News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hythiam, Inc. Announces First Peer-Reviewed Publication of Statistically Significant Results from Randomized, Double-Blind, Placebo-Controlled Study


9/28/2009 10:09:10 AM

LOS ANGELES--(BUSINESS WIRE)--Hythiam, Inc. (NASDAQ:HYTM) announced today that the results of a double-blind, placebo-controlled study on the impact of the medical component of the PROMETA® Treatment Program on alcohol dependent subjects was accepted and published in the Journal of Clinical Psychopharmacology, a leading scholarly publication in psychopharmacology that features articles reporting on clinical trials and studies. The article is titled, “Efficacy of a Combination of Flumazenil and Gabapentin in the Treatment of Alcohol Dependence”, Anton RF, Myrick H., et al., Journal of Clinical Psychopharmacology, Volume 29, Number 4, August 2009, pp. 334-342. The study was conducted at the Medical University of South Carolina, and among the researchers’ findings were that key results demonstrated a statistically significant difference in use for subjects who exhibited pre-treatment withdrawal symptoms. The results are the first to be published in a peer-reviewed scientific journal from a double-blind, placebo-controlled study conducted to assess the impact of the PROMETA Treatment Program on alcohol dependence.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES